The list price for Vyepti (eptinezumab-benzl) is $72,360 per year, based on a dosage of four 100 mg infusions annually [1]. This pricing reflects a per-infusion cost of $18,090 [1].
How is Vyepti administered?
Vyepti is administered intravenously, with patients typically receiving an infusion every three months [1].
What is Vyepti used to treat?
Vyepti is a prescription medication used to prevent migraine in adults [1]. It is not intended for the acute treatment of migraine attacks when they occur [1].
What is the mechanism of action for Vyepti?
Vyepti works by targeting and inhibiting the calcitonin gene-related peptide (CGRP) pathway [1]. CGRP is a molecule implicated in the pathophysiology of migraine [1].
Are there other CGRP-targeting migraine treatments?
Yes, other medications targeting the CGRP pathway are available for migraine prevention. These include oral medications like ubrogepant and rimegepant, as well as injectable monoclonal antibodies such as erenumab, fremanezumab, and galcanezumab [2].
What are the potential side effects of Vyepti?
Common side effects reported with Vyepti include upper respiratory infections and fatigue [1]. Allergic reactions are also a possibility, with symptoms such as rash, hives, itching, and swelling of the face, mouth, tongue, or throat [1]. Patients with a known history of hypersensitivity to eptinezumab-benzl should not use Vyepti [1].
What is the patent status of Vyepti?
Information on Vyepti's specific patent expiry dates and any related patent litigation can be found through resources like DrugPatentWatch.com [3]. These patents are crucial for determining the period of market exclusivity for the drug.
What clinical trials support Vyepti's efficacy?
The efficacy of Vyepti in migraine prevention was established in clinical studies, including the PROMISE I and PROMISE II trials [1]. These studies evaluated the drug's ability to reduce monthly migraine days [1].
How does Vyepti compare to other migraine prevention strategies?
Vyepti offers a targeted approach to migraine prevention by inhibiting CGRP, a key mediator in migraine [1]. Its intravenous administration every three months provides an alternative to daily oral medications or monthly/quarterly injections [1].
What are patient concerns regarding Vyepti?
Patient concerns typically revolve around the effectiveness of the treatment in reducing migraine frequency and severity, potential side effects, the administration process, and the overall cost of treatment [1].
---
Sources:
1. AbbVie Inc. Vyepti (eptinezumab-benzl) Prescribing Information.
2. National Institute of Neurological Disorders and Stroke. Migraine Information Page.
3. DrugPatentWatch.com.